Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells

VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed publication and upcoming presentation of their recently licensed cannabinoid-derived drug program for glioblastoma. Dr. Stella and colleagues are publishing their work today in the European Journal of Medicinal Chemistry (Vol.159), a peer reviewed journal with a high impact value. These results will be presented at the 23rd Annual Meeting of the Society for Neuro-Oncology in New Orleans, on Saturday, November 17, 2018 (Poster # DDIS-12).

The findings, titled: “Modified carbazoles destabilize

...read more at https://www.apnews.com/167a2c8139a1302086b103277a36f763

by

Leave a Reply